• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Belimumab: First targeted biological treatment for systemic lupus erythematosus.贝利尤单抗：系统性红斑狼疮的首个靶向生物疗法。
J Pharmacol Pharmacother. 2011 Oct;2(4):317-9. doi: 10.4103/0976-500X.85930.
2
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.贝利尤单抗治疗系统性红斑狼疮患者的疗效和安全性：一项随机、安慰剂对照、3 期临床试验。
Lancet. 2011 Feb 26;377(9767):721-31. doi: 10.1016/S0140-6736(10)61354-2. Epub 2011 Feb 4.
3
Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus.健康志愿者和系统性红斑狼疮患者皮下给予贝利尤单抗的群体药代动力学和药效学分析。
Clin Pharmacokinet. 2018 Jun;57(6):717-728. doi: 10.1007/s40262-017-0586-5.
4
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.贝利尤单抗治疗儿童及成人系统性红斑狼疮的疗效和安全性：一项跨研究比较。
RMD Open. 2021 Sep;7(3). doi: 10.1136/rmdopen-2021-001747.
5
Belimumab: review of use in systemic lupus erythematosus.贝利尤单抗：治疗系统性红斑狼疮的应用评价。
Clin Ther. 2012 May;34(5):1006-22. doi: 10.1016/j.clinthera.2012.02.028. Epub 2012 Mar 30.
6
Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.日本系统性红斑狼疮患者接受贝利尤单抗治疗后的器官系统改善：一项来自 III 期随机安慰剂对照试验的亚组分析。
Mod Rheumatol. 2020 Mar;30(2):313-320. doi: 10.1080/14397595.2019.1630897. Epub 2019 Jul 4.
7
Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus.在接受贝利尤单抗治疗之前，免疫复合物中抗 dsDNA 抗体水平的升高与系统性红斑狼疮患者的临床应答相关。
Arthritis Res Ther. 2019 Nov 29;21(1):259. doi: 10.1186/s13075-019-2056-y.
8
Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine.贝利尤单抗治疗系统性红斑狼疮不会损害对13价肺炎球菌结合疫苗的抗体反应。
Lupus. 2017 Sep;26(10):1072-1081. doi: 10.1177/0961203317695465. Epub 2017 Feb 26.
9
Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan.系统性红斑狼疮（BEAT-LUPUS）试验中 B 细胞耗竭治疗后贝利尤单抗的安全性和疗效：统计分析计划。
Trials. 2020 Jul 16;21(1):652. doi: 10.1186/s13063-020-04391-2.
10
Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration.皮下注射和静脉注射贝利尤单抗治疗系统性红斑狼疮：皮下和静脉给药数据综述。
Expert Rev Clin Immunol. 2017 Oct;13(10):925-938. doi: 10.1080/1744666X.2017.1371592.

引用本文的文献

1
Targeted Cellular Treatment of Systemic Lupus Erythematosus.系统性红斑狼疮的靶向细胞治疗
Cells. 2025 Jan 31;14(3):210. doi: 10.3390/cells14030210.
2
Systemic Lupus Erythematous: Gene Polymorphisms, Epigenetics, Environmental, Hormonal and Nutritional Factors in the Consideration of Personalized Therapy.系统性红斑狼疮：个性化治疗考量中的基因多态性、表观遗传学、环境、激素及营养因素
Arch Intern Med Res. 2024;7(4):331-340. doi: 10.26502/aimr.0188. Epub 2024 Dec 24.
3
Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS).中重度系统性红斑狼疮患者的真实世界治疗模式及临床特征：一项系统性红斑狼疮前瞻性观察队列研究（SPOCS）的分析
Lupus Sci Med. 2025 Jan 23;12(1):e001336. doi: 10.1136/lupus-2024-001336.
4
Longitudinal associations of flare and damage accrual in patients with systemic lupus erythematosus.系统性红斑狼疮患者中病情活动与损伤累积的纵向关联
Lupus Sci Med. 2025 Jan 19;12(1):e001363. doi: 10.1136/lupus-2024-001363.
5
CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives.用于系统性红斑狼疮的嵌合抗原受体T细胞疗法：现状与未来展望
Front Immunol. 2024 Dec 19;15:1476859. doi: 10.3389/fimmu.2024.1476859. eCollection 2024.
6
CAR-T-Cell Therapy for Systemic Lupus Erythematosus: A Comprehensive Overview.嵌合抗原受体 T 细胞疗法治疗系统性红斑狼疮：全面综述。
Int J Mol Sci. 2024 Sep 29;25(19):10511. doi: 10.3390/ijms251910511.
7
Targeting TNF/TNFR superfamilies in immune-mediated inflammatory diseases.针对免疫介导的炎症性疾病中的 TNF/TNFR 超家族。
J Exp Med. 2024 Nov 4;221(11). doi: 10.1084/jem.20240806. Epub 2024 Sep 19.
8
Infectious Disease Prophylaxis During and After Immunosuppressive Therapy.免疫抑制治疗期间及之后的传染病预防
Kidney Int Rep. 2024 Apr 25;9(8):2337-2352. doi: 10.1016/j.ekir.2024.04.043. eCollection 2024 Aug.
9
Systemic lupus erythematosus therapeutic strategy: From immunotherapy to gut microbiota modulation.系统性红斑狼疮治疗策略：从免疫疗法到肠道微生物群调节。
J Biomed Res. 2024 May 25;38(6):1-16. doi: 10.7555/JBR.38.20240009.
10
Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease.达雷妥尤单抗单药治疗难治性温抗体自身免疫性溶血性贫血和冷凝集素病。
Blood Adv. 2024 Jun 11;8(11):2622-2634. doi: 10.1182/bloodadvances.2024012585.

本文引用的文献

1
An update on belimumab for the treatment of lupus.贝利尤单抗治疗狼疮的最新进展。
Biologics. 2011;5:33-43. doi: 10.2147/BTT.S13804. Epub 2011 Feb 14.
2
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.贝利尤单抗治疗系统性红斑狼疮患者的疗效和安全性：一项随机、安慰剂对照、3 期临床试验。
Lancet. 2011 Feb 26;377(9767):721-31. doi: 10.1016/S0140-6736(10)61354-2. Epub 2011 Feb 4.
3
Advances in drug therapy for systemic lupus erythematosus.系统性红斑狼疮的药物治疗进展。
BMC Med. 2010 Nov 29;8:77. doi: 10.1186/1741-7015-8-77.
4
New and emerging treatment approaches to lupus.狼疮的新型及新兴治疗方法。
Biologics. 2010 Sep 13;4:263-71. doi: 10.2147/btt.s7581.
5
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.利妥昔单抗治疗中度至重度活动性系统性红斑狼疮的疗效和安全性：利妥昔单抗治疗系统性红斑狼疮的随机、双盲、II/III期试验
Arthritis Rheum. 2010 Jan;62(1):222-33. doi: 10.1002/art.27233.
6
Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study.抗 dsDNA、抗核小体和抗α-辅肌动蛋白抗体与狼疮肾炎患者肾脏疾病标志物的关系：一项前瞻性纵向研究。
Arthritis Res Ther. 2009 Oct 14;11(5):R154. doi: 10.1186/ar2831.
7
The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus.B淋巴细胞刺激因子（BLyS）在系统性红斑狼疮中的作用。
J Clin Invest. 2009 May;119(5):1066-73. doi: 10.1172/JCI38010. Epub 2009 May 1.
8
Understanding the epidemiology and progression of systemic lupus erythematosus.了解系统性红斑狼疮的流行病学和进展。
Semin Arthritis Rheum. 2010 Feb;39(4):257-68. doi: 10.1016/j.semarthrit.2008.10.007. Epub 2009 Jan 10.
9
The BLyS family: toward a molecular understanding of B cell homeostasis.B淋巴细胞刺激因子家族：对B细胞稳态的分子理解
Cell Biochem Biophys. 2009;53(1):1-16. doi: 10.1007/s12013-008-9036-1. Epub 2008 Nov 26.
10
Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.系统性红斑狼疮患者血浆B淋巴细胞刺激因子水平与疾病活动度的相关性
Arthritis Rheum. 2008 Aug;58(8):2453-9. doi: 10.1002/art.23678.

Belimumab: First targeted biological treatment for systemic lupus erythematosus.

作者信息

Dubey Ashok K, Handu Shailendra S, Dubey Suparna, Sharma Prashant, Sharma K K, Ahmed Qazi M

机构信息

Department of Pharmacology, School of Medical Sciences and Research, Sharda University, Gr. Noida, India.

出版信息

J Pharmacol Pharmacother. 2011 Oct;2(4):317-9. doi: 10.4103/0976-500X.85930.

DOI:10.4103/0976-500X.85930
PMID:22025872
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3198539/
Abstract
摘要